Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS.

Gafson AR, Kim K, Cencioni MT, van Hecke W, Nicholas R, Baranzini SE, Matthews PM.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 12;5(4):e470. doi: 10.1212/NXI.0000000000000470. eCollection 2018 Jul.

2.

Remote Monitoring in the Home Validates Clinical Gait Measures for Multiple Sclerosis.

Supratak A, Datta G, Gafson AR, Nicholas R, Guo Y, Matthews PM.

Front Neurol. 2018 Jul 13;9:561. doi: 10.3389/fneur.2018.00561. eCollection 2018.

3.

Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.

Raffel J, Gafson AR, Dahdaleh S, Malik O, Jones B, Nicholas R.

PLoS One. 2017 Jan 12;12(1):e0169546. doi: 10.1371/journal.pone.0169546. eCollection 2017.

4.

Anti-JC virus antibody titres increase over time with natalizumab treatment.

Raffel J, Gafson AR, Malik O, Nicholas R.

Mult Scler. 2015 Dec;21(14):1833-8. doi: 10.1177/1352458515599681. Epub 2015 Oct 8.

5.

CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age.

Gafson AR, Giovannoni G.

Mult Scler Relat Disord. 2014 Mar;3(2):143-6. doi: 10.1016/j.msard.2013.10.005. Epub 2013 Oct 22.

PMID:
25878001
6.

Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis.

Gafson AR, Giovannoni G.

Mult Scler. 2012 Oct;18(10):1509-11. Epub 2012 Feb 1. No abstract available.

PMID:
22298590
7.

Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.

Gafson AR, Goodkin O, Begent R.

BMJ Case Rep. 2010 Nov 9;2010. pii: bcr0420102869. doi: 10.1136/bcr.04.2010.2869.

Supplemental Content

Loading ...
Support Center